Ongoing challenges of off-label prescribing.

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Drug Regulation

Background:

• Off-label prescribing deviates from approved product information regarding indications, doses, routes, or patient groups.
• It is prevalent, particularly in vulnerable populations often excluded from clinical trials, such as pediatric and pregnant patients.
• This practice carries potential risks including increased prescriber liability and patient costs if the medication is not subsidized for the unapproved use.

Purpose of the Study:

• To highlight the commonality and implications of off-label prescribing.
• To emphasize the importance of informed consent and risk-benefit communication for patients receiving off-label medications.
• To suggest alternative regulatory pathways to mitigate off-label prescribing.

Main Methods:

• This study is a review of current practices and risks associated with off-label prescribing.
• Analysis of Australian approved product information and prescribing guidelines.
• Discussion of legal and financial implications for prescribers and patients.

Main Results:

• Off-label prescribing is a widespread practice, particularly in pediatric and obstetric care.
• Lack of supporting evidence or guidelines increases prescriber liability and potential for adverse events.
• Patients may incur additional costs for unsubsidized off-label treatments.

Conclusions:

• Prescribers must ensure patients are fully informed about the off-label status, potential benefits, and harms of prescribed medications.
• Establishing alternative approval pathways for new indications, doses, and patient groups could reduce reliance on off-label prescribing.
• Clear communication and regulatory adaptations are crucial for safe and effective patient care.